Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2018

Open Access 01-12-2018 | Review

Alzheimer’s disease hypothesis and related therapies

Authors: Xiaoguang Du, Xinyi Wang, Meiyu Geng

Published in: Translational Neurodegeneration | Issue 1/2018

Login to get access

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause for dementia. There are many hypotheses about AD, including abnormal deposit of amyloid β (Aβ) protein in the extracellular spaces of neurons, formation of twisted fibers of tau proteins inside neurons, cholinergic neuron damage, inflammation, oxidative stress, etc., and many anti-AD drugs based on these hypotheses have been developed. In this review, we will discuss the existing and emerging hypothesis and related therapies.
Literature
1.
Ali G-C, Guerchet M, Wu Y-T, Prince M, Prina M. Chapter 2: The global prevalence of dementia. In: Prince M, Guerchet M, Ali G-C, Wu Y-T, Prina M, editors. The Global Impact of Dementia. An analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International (ADI); 2015. p. 10–29.
2.
3.
Vassar R, Citron M. Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron. 2000;27(3):419–22.PubMedCrossRef
4.
van Es JH, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435(7044):959–63.PubMedCrossRef
5.
Olry A, et al. Generation and characterization of mutant cell lines defective in gamma-secretase processing of notch and amyloid precursor protein. J Biol Chem. 2005;280(31):28564–71.PubMedCrossRef
6.
Tarassishin L, et al. Processing of notch and amyloid precursor protein by gamma-secretase is spatially distinct. Proc Natl Acad Sci U S A. 2004;101(49):17050–5.PubMedPubMedCentralCrossRef
7.
Sastre M, et al. Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of notch. EMBO Rep. 2001;2(9):835–41.PubMedPubMedCentralCrossRef
8.
Klaver DW, et al. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer’s disease? Current strategies and future directions. Biol Chem. 2010;391(8):849–59.PubMedCrossRef
9.
Abramov E, et al. Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci. 2009;12(12):1567–76.PubMedCrossRef
10.
Gilman S, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in AN interrupted trial. Neurology. 2005;64(9):1553–62.PubMedCrossRef
11.
Bayer AJ, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005;64(1):94–101.PubMedCrossRef
12.
Holmes C, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216–23.PubMedCrossRef
13.
Laskowitz DT, Kolls BJ. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2010;74(24):2026. author reply 2026-7PubMedCrossRef
14.
15.
16.
Bouter Y, et al. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against Ntruncated Abeta in sporadic Alzheimer disease cases and mouse models. Acta Neuropathol. 2015;130(5):713–29.PubMedCrossRef
17.
The Lancet N. Solanezumab: too late in mild Alzheimer’ss disease? Lancet Neurol. 2017;16(2):97.CrossRef
18.
Gandy S, Sano M. Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD? Nat Rev Neurol. 2015;11(12):669–70.PubMedCrossRef
19.
Landen JW, et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol. 2013;36(1):14–23.PubMedCrossRef
20.
Burstein AH, et al. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin Neuropharmacol. 2013;36(1):8–13.PubMedCrossRef
21.
La Porte SL, et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012;421(4–5):525–36.PubMedCrossRef
22.
Carlson C, et al. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease. Alzheimers Dement (Amst). 2016;2:75–85.
23.
24.
Aisen PS, et al. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase study). Arch Med Sci. 2011;7(1):102–11.PubMedPubMedCentralCrossRef
25.
Greenberg SM, et al. A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord. 2006;20(4):269–74.PubMedCrossRef
26.
Gervais F, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007;28(4):537–47.PubMedCrossRef
27.
Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698–712.PubMedCrossRef
28.
Nie Q, Du XG, Geng MY. Small molecule inhibitors of amyloid beta peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. Acta Pharmacol Sin. 2011;32(5):545–51.PubMedPubMedCentralCrossRef
29.
Sevigny J, et al. Addendum: the antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature. 2017;546(7659):564.PubMedCrossRef
30.
Sevigny J, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature. 2016;537(7618):50–6.PubMedCrossRef
31.
Patel KR. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source. Manag Care. 2015;24(6):19.
32.
33.
Siemers ER, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 2016;12(2):110–20.PubMedCrossRef
34.
Barrera-Ocampo A, Lopera F. Amyloid-beta immunotherapy: the hope for Alzheimer disease? Colomb Med (Cali). 2016;47(4):203–12.
35.
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5.PubMedCrossRef
36.
37.
Wang J, et al. A systemic view of Alzheimer disease - insights from amyloid-beta metabolism beyond the brain. Nat Rev Neurol. 2017;13(10):612–23.PubMedCrossRef
38.
39.
Morris M, et al. Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci. 2015;18(8):1183–9.PubMedCrossRef
40.
Gauthier S, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388(10062):2873–84.PubMedPubMedCentralCrossRef
41.
Novak P, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16(2):123–34.PubMedCrossRef
42.
Li C, Gotz J. Tau-based therapies in neurodegeneration: opportunities and challenges. Nat Rev Drug Discov. 2017;
43.
44.
45.
Song W, et al. Alzheimer's disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement. 2017;13(4):381–7.PubMedCrossRef
46.
Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016;17(4):201–7.PubMedCrossRef
47.
Bolos M, Perea JR, Avila J. Alzheimer's disease as an inflammatory disease. Biomol Concepts. 2017;8(1):37–43.PubMedCrossRef
48.
Hong S, Dissing-Olesen L, Stevens B. New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol. 2016;36:128–34.PubMedCrossRef
49.
Paolicelli RC, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333(6048):1456–8.PubMedCrossRef
50.
Bliss TV, Collingridge GL, Morris RG. Synaptic plasticity in health and disease: introduction and overview. Philos Trans R Soc Lond Ser B Biol Sci. 2014;369(1633):20130129.CrossRef
51.
Chen J, et al. Inhibition of AGEs/RAGE/rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-kappaB pathway. J Neuroimmunol. 2017;305:108–14.PubMedCrossRef
52.
Hirbec H E, Noristani HN, Perrin FE. Microglia Responses in Acute and Chronic Neurological Diseases: What Microglia-Specific Transcriptomic Studies Taught (and did Not Teach) Us. Front Aging Neurosci. 2017;9:227.CrossRef
53.
Baruch K, et al. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. Nat Med. 2016;22(2):135–7.PubMedCrossRef
54.
Saresella M, et al. A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease. Neurobiol Aging. 2012;33(3):624 e11–22.CrossRef
55.
Saresella M, et al. PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2010;21(3):927–38.PubMedCrossRef
56.
Jevtic S, et al. The role of the immune system in Alzheimer disease: etiology and treatment. Ageing Res Rev. 2017;40:84–94.PubMedCrossRef
57.
McGeer PL, McGeer EG. Targeting microglia for the treatment of Alzheimer's disease. Expert Opin Ther Targets. 2015;19(4):497–506.PubMedCrossRef
58.
Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017;23(9):1018–27.PubMedCrossRef
59.
Hasselmo ME, Anderson BP, Bower JM. Cholinergic modulation of cortical associative memory function. J Neurophysiol. 1992;67(5):1230–46.PubMedCrossRef
60.
Fine A, et al. Learning impairments following injection of a selective cholinergic immunotoxin, ME20.4 IgG-saporin, into the basal nucleus of Meynert in monkeys. Neuroscience. 1997;81(2):331–43.PubMedCrossRef
61.
Sarter M, Bruno JP. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev. 1997;23(1–2):28–46.PubMedCrossRef
62.
Miranda MI, Bermudez-Rattoni F. Reversible inactivation of the nucleus basalis magnocellularis induces disruption of cortical acetylcholine release and acquisition, but not retrieval, of aversive memories. Proc Natl Acad Sci U S A. 1999;96(11):6478–82.PubMedPubMedCentralCrossRef
63.
Haam J, Yakel JL. Cholinergic modulation of the hippocampal region and memory function. J Neurochem. 2017;142(Suppl 2):111–21.PubMedCrossRef
64.
Brinkman SD, Gershon S. Measurement of cholinergic drug effects on memory in Alzheimer's disease. Neurobiol Aging. 1983;4(2):139–45.PubMedCrossRef
65.
Summers WK, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986;315(20):1241–5.PubMedCrossRef
66.
Summers WK, et al. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry. 1981;16(2):145–53.PubMed
67.
Cheignon C, et al. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018;14:450–64.PubMedCrossRef
68.
Sultana R, Butterfield DA. Redox proteomics studies of in vivo amyloid beta-peptide animal models of Alzheimer's disease: insight into the role of oxidative stress. Proteomics Clin Appl. 2008;2(5):685–96.PubMedCrossRef
69.
Butterfield DA, et al. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med. 2007;43(5):658–77.PubMedPubMedCentralCrossRef
70.
Mohmmad Abdul H, et al. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease. J Neurochem. 2006;96(5):1322–35.PubMedCrossRef
71.
Gibson GL, Allsop D, Austen BM. Induction of cellular oxidative stress by the beta-amyloid peptide involved in Alzheimer's disease. Protein Pept Lett. 2004;11(3):257–70.PubMedCrossRef
72.
Butterfield DA, et al. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis. 2002;4(3):193–201.PubMedCrossRef
73.
Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med. 2002;32(11):1050–60.PubMedCrossRef
74.
Persson T, Popescu BO, Cedazo-Minguez A. Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail? Oxidative Med Cell Longev. 2014;2014:427318.CrossRef
75.
Teixeira J, et al. Alzheimer's disease and antioxidant therapy: how long how far? Curr Med Chem. 2013;20(24):2939–52.PubMedCrossRef
76.
Caldwell CC, Yao J, Brinton RD. Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities. Neurotherapeutics. 2015;12(1):66–80.PubMedCrossRef
77.
Daulatzai MA. Cerebral hypoperfusion and glucose hypometabolism: key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. J Neurosci Res. 2017;95(4):943–72.PubMedCrossRef
78.
79.
80.
Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35:369–89.PubMedCrossRef
81.
82.
83.
Erickson MA, Dohi K, Banks WA. Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier. Neuroimmunomodulation. 2012;19(2):121–30.PubMedPubMedCentralCrossRef
84.
Banks WA. The blood-brain barrier in neuroimmunology: Tales of separation and assimilation. Brain Behav Immun. 2015;44:1–8.PubMedCrossRef
85.
Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012;10(11):735–42.PubMedCrossRef
86.
Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701–12.PubMedCrossRef
87.
88.
89.
90.
91.
Tomkovich S, Jobin C. Microbiota and host immune responses: a love-hate relationship. Immunology. 2016;147(1):1–10.PubMedCrossRef
92.
Agace WW, McCoy KD. Regionalized development and maintenance of the intestinal adaptive immune landscape. Immunity. 2017;46(4):532–48.PubMedCrossRef
93.
94.
95.
Sudo N, et al. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol. 2004;558(Pt 1):263–75.PubMedPubMedCentralCrossRef
96.
O'Mahony SM, et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015;277:32–48.PubMedCrossRef
97.
Praveen V, Praveen S. Microbiome-gut-brain Axis: a pathway for improving brainstem serotonin homeostasis and successful autoresuscitation in SIDS-A novel hypothesis. Front Pediatr. 2016;4:136.PubMed
98.
Jiang XG, et al. Research progress in anti-inflammation of vagus nerve and neurotransmitter ach. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2003;15(1):59–61.PubMed
99.
Das UN. Vagus nerve stimulation, depression, and inflammation. Neuropsychopharmacology. 2007;32(9):2053–4.PubMedCrossRef
100.
Browning KN, Verheijden S, Boeckxstaens GE. The Vagus nerve in appetite regulation, mood, and intestinal inflammation. Gastroenterology. 2017;152(4):730–44.PubMedCrossRef
101.
de Haan JJ, et al. Exploring the link between inflammation and the vagus nerve. J Intern Med. 2010;267(1):130–1.PubMedCrossRef
102.
Hoeger S, et al. Modulation of brain dead induced inflammation by vagus nerve stimulation. Am J Transplant. 2010;10(3):477–89.PubMedCrossRef
103.
104.
Gordon JI, et al. The human gut microbiota and undernutrition. Sci Transl Med. 2012;4(137):137ps12.PubMedCrossRef
105.
Mitchell RW, et al. Fatty acid transport protein expression in human brain and potential role in fatty acid transport across human brain microvessel endothelial cells. J Neurochem. 2011;117(4):735–46.PubMed
106.
107.
Zhao Y, Dua P, Lukiw WJ. Microbial sources of amyloid and relevance to Amyloidogenesis and Alzheimer's disease (AD). J Alzheimers Dis Parkinsonism. 2015;5(1):177.PubMedPubMedCentral
108.
109.
110.
Quigley EMM. Microbiota-brain-gut Axis and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2017;17(12):94.PubMedCrossRef
111.
Cattaneo A, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging. 2017;49:60–8.PubMedCrossRef
112.
Park AM, et al. Helicobacter pylori and gut microbiota in multiple sclerosis versus Alzheimer's disease: 10 pitfalls of microbiome studies. Clin Exp Neuroimmunol. 2017;8(3):215–32.PubMedCrossRef
113.
Chen F, et al. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? J Ethnopharmacol. 2016;179:253–64.PubMedCrossRef
114.
Zheng X, et al. Thinking outside the brain for cognitive improvement: Is peripheral immunomodulation on the way? Neuropharmacology. 2015;96(Pt A):94–104.PubMedCrossRef
115.
Yang WT, et al. Chinese herbal medicine for Alzheimer's disease: clinical evidence and possible mechanism of neurogenesis. Biochem Pharmacol. 2017;141:143–55.PubMedCrossRef
Metadata
Title
Alzheimer’s disease hypothesis and related therapies
Authors
Xiaoguang Du
Xinyi Wang
Meiyu Geng
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2018
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-018-0107-y

Other articles of this Issue 1/2018

Translational Neurodegeneration 1/2018 Go to the issue

Review

Hydrogen sulfide, nitric oxide, and neurodegenerative disorders

Review

The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms

Research

CSF Aβ1–42 level is associated with cognitive decline in early Parkinson’s disease with rapid eye movement sleep behavior disorder

Short report

Rare TBK1 variants in patients with frontotemporal dementia and amyotrophic lateral sclerosis in a Chinese cohort

Review

Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?

Review

Cerebral glucose metabolic prediction from amnestic mild cognitive impairment to Alzheimer’s dementia: a meta-analysis